Page last updated: 2024-11-05

1,2,3-trichloropropane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID7285
CHEMBL ID346933
CHEBI ID34036
SCHEMBL ID19623
MeSH IDM0054329

Synonyms (64)

Synonym
BIDD:ER0690
propane, 1,2,3-trichloro-
glyceryl trichlorohydrin
propane,2,3-trichloro-
96-18-4
1,3-trichloropropane
nsc35403
allyl trichloride
glycerol trichlorohydrin
trichlorohydrin
wln: g1yg1g
nsc-35403
ai3-26040
nci-c60220
nsc 35403
ccris 5874
trichloropropane, 1,2,3-
einecs 202-486-1
brn 1732068
glycerin trichlorohydrin
hsdb 1340
NCGC00090694-01
1,2,3-trichloropropane
1,2,3-trichloropropane, analytical standard
1,2,3-trichloropropane, 99%
NCGC00090694-02
1,2,3-trichloro-propane
CHEMBL346933
chebi:34036 ,
S0655
T0395
STK802057
AKOS005622729
NCGC00090694-03
unii-3mj7qck0z0
3mj7qck0z0 ,
ec 202-486-1
dtxcid401390
cas-96-18-4
NCGC00256369-01
tox21_302963
dtxsid9021390 ,
tox21_202023
NCGC00259572-01
BBL010950
FT-0606227
1,2,3-trichloropropane [iarc]
1,2,3-trichloropropane [hsdb]
morpholino(4-pyridyl)methanone
SCHEMBL19623
1,2,3trichloropropane
203578-27-2
mfcd00000946
1,2,3-trichloropropane, tracecert(r)
1,2,3-trichloropropane 100 microg/ml in methanol
epa method 552.3 is solution 1,2,3-trichloropropane, 1000 microg/ml in methanol
1,2,3-trichloropropane 10 microg/ml in methanol
VS-02765
Q161301
AMY22833
1,2,3-trichloropropane (d5)
D97722
111 - vocs (fumigants) in groundwater
55 - vocs (fumigants) in groundwater

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" A physiological pharmacokinetic model was developed to describe the time course of trichloropropane concentration in tissues."( Disposition of 1,2,3-trichloropropane in the Fischer 344 rat: conventional and physiological pharmacokinetics.
Carter, DE; Falcoz, C; Gross, JF; Sipes, IG; Volp, RF, 1984
)
0.62

Dosage Studied

ExcerptRelevanceReference
" Male mice eliminated TCP-derived radioactivity more rapidly than rats and lower concentrations of radioactivity were found in tissues 60 hr after dosing in mice."( Comparative disposition and metabolism of 1,2,3-trichloropropane in rats and mice.
Burka, LT; Mahmood, NA; Overstreet, D,
)
0.4
" Calculated were a reference dose (=39 microg/kg d) for non-cancer and Cancer Values (CV) (=10-14 microg/kg d) based on non-linear dose-response relationships for mutagenicity as a precursor of cancer."( Derivation of a reference dose and drinking water equivalent level for 1,2,3-trichloropropane.
Carson, ML; Tardiff, RG, 2010
)
0.59
" Since publication of EPA's 2005 Guidelines for Carcinogen Risk Assessment, IRIS cancer assessments have implemented new approaches recommended in these guidelines and expanded the use of complex scientific methods to perform quantitative dose-response assessments."( Approaches to cancer assessment in EPA's Integrated Risk Information System.
Gehlhaus, MW; Gift, JS; Hogan, KA; Kadry, AR; Kopylev, L; Schlosser, PM, 2011
)
0.37
" This context is explored based on MOA analyses in published assessments to illustrate the relative extent of supporting data and their implications for dose-response analysis and involved comparisons for chemical assessments on trichloropropane, and carbon tetrachloride with several hypothesized MOA(s) for cancer."( Mode of action human relevance (species concordance) framework: Evolution of the Bradford Hill considerations and comparative analysis of weight of evidence.
Bachman, AN; Jeffrey Lewis, R; Meek, ME; North, CM; Palermo, CM, 2014
)
0.4
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organochlorine compoundAn organochlorine compound is a compound containing at least one carbon-chlorine bond.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (4)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
GLI family zinc finger 3Homo sapiens (human)Potency14.14130.000714.592883.7951AID1259369
estrogen receptor 2 (ER beta)Homo sapiens (human)Potency27.52830.000657.913322,387.1992AID1259377
estrogen nuclear receptor alphaHomo sapiens (human)Potency41.79370.000229.305416,493.5996AID743069; AID743075; AID743079
peroxisome proliferator-activated receptor deltaHomo sapiens (human)Potency7.82710.001024.504861.6448AID743215
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (3)

Assay IDTitleYearJournalArticle
AID37563Aneuploidy activity was determined; - indicates negative induction of aneuploidy in Aspergillus nidulans1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Molecular similarity matrices and quantitative structure-activity relationships: a case study with methodological implications.
AID433903Hepatotoxicity in mouse assessed as carcinogenic potency2009European journal of medicinal chemistry, Sep, Volume: 44, Issue:9
Development of QSAR models for predicting hepatocarcinogenic toxicity of chemicals.
AID19825Partition coefficient (logP)1995Journal of medicinal chemistry, Feb-17, Volume: 38, Issue:4
Molecular similarity matrices and quantitative structure-activity relationships: a case study with methodological implications.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (63)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (6.35)18.7374
1990's11 (17.46)18.2507
2000's13 (20.63)29.6817
2010's30 (47.62)24.3611
2020's5 (7.94)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 43.93

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index43.93 (24.57)
Research Supply Index4.19 (2.92)
Research Growth Index4.97 (4.65)
Search Engine Demand Index63.85 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (43.93)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews5 (7.69%)6.00%
Case Studies4 (6.15%)4.05%
Observational0 (0.00%)0.25%
Other56 (86.15%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]